Insider Selling: Pediatrix Medical Group, Inc. (NYSE:MD) Director Sells 27,600 Shares of Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Pediatrix Medical Group Trading Down 4.1 %

NYSE MD opened at $14.15 on Friday. The stock has a market capitalization of $1.22 billion, a P/E ratio of -4.62, a P/E/G ratio of 2.18 and a beta of 1.55. The business has a 50 day simple moving average of $12.53 and a 200 day simple moving average of $9.84. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. Pediatrix Medical Group, Inc. has a one year low of $6.62 and a one year high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter in the prior year, the firm earned $0.29 EPS. The business’s revenue was up .9% on a year-over-year basis. Research analysts expect that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in Pediatrix Medical Group in the 2nd quarter valued at $31,000. Innealta Capital LLC bought a new position in Pediatrix Medical Group during the second quarter valued at about $33,000. Quest Partners LLC increased its holdings in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after buying an additional 622 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after acquiring an additional 1,524 shares during the period. Finally, Quarry LP boosted its stake in Pediatrix Medical Group by 54.1% in the third quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after acquiring an additional 1,662 shares during the last quarter. 97.71% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research report on Monday, November 4th. StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft upped their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, UBS Group raised their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $16.10.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.